According to the report, The Middle-East and Africa Lung Cancer Therapeutics Market size was worth USD 0.76 billion in 2022 and estimated to be growing at a CAGR of 6.59%, to reach USD 1.04 billion by 2027.
Medical improvements have presented effective methods for the treatment of lung cancer. Presently, surgery, chemotherapy, and radiation therapy are foremost treatment possibilities implemented. Lung cancer is treated majorly with chemotherapy and radiation therapy. The primary lung carcinomas originate from epithelial cells.
The Middle-East and Africa lung cancer therapeutics market would be driven by growing acceptance of modified treatments. Though new drugs have restored the lung cancer therapeutics market, patent expiry of existing drugs has postured a major risk to original drug manufacturers.
Still, this has also shaped new chances for generic drug manufacturers to promote low-cost generic drugs.
This research report on the MEA Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:
By Treatment Type:
Regionally, Middle-East is anticipated to witness high growth in the forecast period and Africa is expected to dominate the Middle-East and Africa region lung cancer therapeutics market.
The leading companies leading in the MEA Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com